Close Menu

NEW YORK (GenomeWeb) – MDNA Life Sciences announced today that it has signed an agreement making BL&H the exclusive South Korean distributor of its PCR-based liquid biopsy prostate cancer test, the Prostate Mitomic Test (PMT).

PMT analyzes the mitochondrial genome to determine which men with clinical suspicion of prostate cancer are likely to have high-grade disease that may require immediate intervention. The test's negative predictive value can also help identify cases that can safely delay or forego immediate biopsy.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.